Skip to main
DCTH

Delcath Systems (DCTH) Stock Forecast & Price Target

Delcath Systems (DCTH) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Delcath Systems Inc. has reported a remarkable 140% growth in Hepzato procedure volume in 2025, indicating rising physician adoption and increased utilization of their treatment options. The company's year-end cash balance reached $91.0 million, showing a slight yet positive increase from the previous quarter, highlighting operational efficiency and financial stability. Furthermore, with plans for salesforce expansion in 2026 and expectations for the upcoming CHOPIN trial data to enhance clinical adoption, the outlook remains positive as these initiatives are anticipated to bolster Hepzato's market presence and drive revenue growth.

Bears say

Delcath Systems Inc. has revised its full-year revenue expectations down to $83 million-$85 million, significantly lower than the previous range of $93 million-$96 million, primarily due to a slowdown in new site activations and decreased patient starts attributed to summer seasonality and competitive clinical trials. Additionally, the company is facing declining average revenue per kit as a result of the Medicaid National Drug Rebate Agreement, with anticipated discounts impacting half of their patient base at approximately 23%. Lastly, Delcath Systems is currently cash flow negative, raising concerns regarding its ability to sustain operations and achieve forecasted revenue levels in the future.

Delcath Systems (DCTH) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Delcath Systems and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Delcath Systems (DCTH) Forecast

Analysts have given Delcath Systems (DCTH) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Delcath Systems (DCTH) has a Strong Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Delcath Systems (DCTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.